New Rheumatoid Arthritis Drug

PBIRx®
Intelligent Solutions in Pharmacy Benefits
12 Wheelers Farms Road, Milford, CT 06461
(888) 797-2479

On May 22, 2017, the FDA approved a new drug, Kevzara (sarilumab), manufactured by Sanofi/Regeneron Pharmaceuticals, indicated to treat adults with moderate-to-severe rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs.  The patient receives one injection every two weeks at a cost of approximately $39,000 per year.  

This new drug will come with a boxed warning that cautions it may predispose patients to bacterial, fungal, viral or other infections.  Before use, patients should be tested for latent tuberculosis. PBIRx will continue to keep our members informed of the latest drugs available as well as their possible side effects.   PBIRx has been exclusively providing intelligent solutions to clients in the management of pharmacy benefit costs since 1993. With a staff that includes IT personnel, actuaries, financial analysts, clinical pharmacists, attorneys, HIPAA Compliance Officers and many more experts, PBIRx’s mission is to create optimal health care outcomes while minimizing overall health care costs. For more information, please visit www.pbirx.com or call (888) 797-2479.